PMID- 33457258
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210119
IS  - 2223-4691 (Print)
IS  - 2223-4691 (Electronic)
IS  - 2223-4683 (Linking)
VI  - 9
IP  - 6
DP  - 2020 Dec
TI  - Anaplastic lymphoma kinase (ALK) rearrangement in adult renal cell carcinoma with 
      lung metastasis: a case report and literature review.
PG  - 2855-2861
LID - 10.21037/tau-20-1343 [doi]
AB  - Renal cell carcinoma (RCC) with anaplastic lymphoma kinase (ALK) rearrangement is 
      rare, and the genetic profiles of the tumor have not been elucidated. Here, we 
      report a case with recurrent papillary RCC and lung metastasis after nephrectomy 
      for nearly 7 years. The patient first received sunitinib, whereas the drug 
      toxicity was intolerable. Combined Immunohistology (IHC) and fluorescence in situ 
      hybridization (FISH) revealed the patient has an ALK rearrangement, and the 
      patient then was treated with crizotinib. The patient had good tolerance, and a 
      partial response in the target lesions was achieved. In order to further 
      understand the benefit of crizotinib in ALK-rearranged RCC, the patient was 
      detected with whole exome sequencing (WES) to study her genetic profiles. 
      Compared those of RCC cases without ALK rearrangement (nALK-RCC), the patient and 
      nine RCC cases with ALK rearrangement (ALK-RCC) revealed unique genetic 
      characteristics: 1) The common mutations that occurred in RCC were not found in 
      ALK-RCC.; 2) A total of 11 co-existing mutations in ALK-RCC were found, and they 
      occurred in nALK-RCC at a relatively low frequency. DNMT3A mutations were 
      concurrent with ALK fusions in our case. These findings indicated a different 
      genetic alteration pattern of ALK-RCC from nALK-RCC. Our case demonstrated the 
      efficacy of crizotinib in an RCC patient with ALK rearrangement.
CI  - 2020 Translational Andrology and Urology. All rights reserved.
FAU - Zhou, Shengyu
AU  - Zhou S
AD  - Department of Medical Oncology, National Cancer Center/National Clinical Research 
      Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and 
      Peking Union Medical College (PUMC), Beijing, China.
FAU - Sun, Guanxing
AU  - Sun G
AD  - Department of Medical Oncology, Zaozhuang Municipal Hospital, Zaozhuang, China.
FAU - Wang, Jianwei
AU  - Wang J
AD  - Department of Medical Oncology, National Cancer Center/National Clinical Research 
      Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and 
      Peking Union Medical College (PUMC), Beijing, China.
FAU - Zhang, Hongtu
AU  - Zhang H
AD  - Department of Medical Oncology, National Cancer Center/National Clinical Research 
      Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and 
      Peking Union Medical College (PUMC), Beijing, China.
LA  - eng
PT  - Case Reports
PL  - China
TA  - Transl Androl Urol
JT  - Translational andrology and urology
JID - 101581119
PMC - PMC7807375
OTO - NOTNLM
OT  - ALK rearrangement
OT  - Renal cell carcinoma (RCC)
OT  - crizotinib
OT  - genomic feature
OT  - lung metastasis
COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure 
      form (available at http://dx.doi.org/10.21037/tau-20-1343). The authors have no 
      conflicts of interest to declare.
EDAT- 2021/01/19 06:00
MHDA- 2021/01/19 06:01
PMCR- 2020/12/01
CRDT- 2021/01/18 05:32
PHST- 2021/01/18 05:32 [entrez]
PHST- 2021/01/19 06:00 [pubmed]
PHST- 2021/01/19 06:01 [medline]
PHST- 2020/12/01 00:00 [pmc-release]
AID - tau-09-06-2855 [pii]
AID - 10.21037/tau-20-1343 [doi]
PST - ppublish
SO  - Transl Androl Urol. 2020 Dec;9(6):2855-2861. doi: 10.21037/tau-20-1343.